Algert Global LLC cut its stake in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 30.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 272,910 shares of the company's stock after selling 120,540 shares during the period. Algert Global LLC owned 0.07% of LifeStance Health Group worth $2,923,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of LFST. BlackRock Inc. acquired a new stake in LifeStance Health Group in the 2nd quarter worth about $389,293,000. Vanguard Group Inc. boosted its stake in shares of LifeStance Health Group by 21.1% in the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company's stock valued at $124,608,000 after purchasing an additional 3,086,506 shares during the period. Silversmith Partners I GP LLC acquired a new stake in LifeStance Health Group in the fourth quarter worth $100,842,000. Dimensional Fund Advisors LP grew its stake in shares of LifeStance Health Group by 16.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company's stock worth $66,038,000 after purchasing an additional 1,461,215 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company's stock worth $65,157,000 after acquiring an additional 2,843,388 shares in the last quarter. Hedge funds and other institutional investors own 85.50% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on the stock. Zacks Research cut shares of LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th. KeyCorp upped their price objective on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company an "overweight" rating in a research report on Monday, July 13th. Wall Street Zen upgraded shares of LifeStance Health Group from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 15th. JPMorgan Chase & Co. boosted their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, August 14th. Finally, The Goldman Sachs Group assumed coverage on LifeStance Health Group in a research report on Friday, June 5th. They set a "neutral" rating and a $9.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $12.38.
Check Out Our Latest Report on LFST
Insiders Place Their Bets
In related news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the sale, the insider owned 98,101,407 shares in the company, valued at $1,041,836,942.34. The trade was a 12.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CTO Vukasin Paunovich sold 44,394 shares of LifeStance Health Group stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $481,674.90. Following the sale, the chief technology officer owned 247,446 shares in the company, valued at $2,684,789.10. The trade was a 15.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 14,629,850 shares of company stock valued at $154,952,012 in the last three months. 3.50% of the stock is owned by corporate insiders.
LifeStance Health Group Stock Performance
Shares of LFST stock opened at $12.31 on Friday. The business has a 50-day simple moving average of $11.19 and a 200-day simple moving average of $8.60. LifeStance Health Group, Inc. has a 52-week low of $4.77 and a 52-week high of $12.97. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.18. The stock has a market cap of $4.77 billion, a PE ratio of 94.70 and a beta of 1.14.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. The company had revenue of $435.35 million during the quarter, compared to analysts' expectations of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The firm's revenue was up 26.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.01) EPS. On average, equities analysts expect that LifeStance Health Group, Inc. will post 0.16 EPS for the current year.
About LifeStance Health Group
(
Free Report)
LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
See Also
Want to see what other hedge funds are holding LFST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
